Emerging therapeutic targets for synovial sarcoma

Area of Science:

• Oncology
• Molecular Biology
• Drug Discovery

Background:

• Synovial sarcoma is a rare soft tissue sarcoma with limited effective treatments for advanced stages.
• Elevated vascular endothelial growth factor (VEGF) expression correlates with higher tumor grade in synovial sarcoma.

Purpose of the Study:

• To review the efficacy and limitations of current and emerging therapeutic targets for advanced synovial sarcoma.
• To summarize drug development achievements and challenges against novel targets.

Main Methods:

• Literature review of preclinical and clinical studies on synovial sarcoma therapeutics.
• Analysis of drug activity targeting VEGF, EGFR, HER2, IGFR-1R, mTOR, CXCR4, and epigenetic/developmental pathways.

Main Results:

• VEGF inhibitors (sorafenib, pazopanib, bevacizumab) demonstrated activity in preclinical models and some clinical use.
• Inhibition of EGFR, HER2, IGFR-1R, and mTOR showed limited meaningful activity in clinical trials.
• Emerging strategies like CXCR4 inhibition, immunotherapy, HDAC inhibitors, and targeting Notch/Hedgehog pathways are under investigation.

Conclusions:

• Targeting VEGF offers a validated approach, but broader efficacy requires exploring newer pathways.
• Significant challenges remain in translating preclinical findings to meaningful clinical activity for advanced synovial sarcoma.
• Future research should focus on novel targets and combination therapies to improve patient outcomes.